TABLE 2.
Effect of diagnosis, age and diagnosis x age interaction on mitochondrial outcomes evaluated in controls, PM and FXTAS female carriers.
| Diagnosis x age interaction | Diagnosis effect | Age effect | |
| Controls vs. PM | |||
| ROS (DFn = 1, DFd = 26) | F = 1.05e-003 | F = 1.45 | F = 0.01 |
| p = 0.9744 | p = 0.2396 | p = 0.9133 | |
| CS (DFn = 1, DFd = 24) | F = 0.57 | F = 4.84 | F = 6.83 |
| p = 0.4560 | p = 0.0377 | p = 0.0153 | |
| M/G (DFn = 1, DFd = 26) | F = 0.07 | F = 4.75 | F = 0.46 |
| p = 0.7989 | p = 0.0385 | p = 0.5019 | |
| S (DFn = 1, DFd = 25) | F = 0.21 | F = 4.80 | F = 0.08 |
| p = 0.6542 | p = 0.0381 | p = 0.7863 | |
| αGP (DFn = 1, DFd = 26) | F = 0.04 | F = 8.08 | F = 0.09 |
| p = 0.8433 | p = 0.0086 | p = 0.7623 | |
| CCO (DFn = 1, DFd = 26) | F = 1.8e-003 | F = 6.82 | F = 0.02 |
| p = 0.9665 | p = 0.0148 | p = 0.9026 | |
| Basal (DFn = 1, DFd = 27) | F = 0.01 | F = 5.94 | F = 4.16e-005 |
| p = 0.9362 | p = 0.0217 | p = 0.9949 | |
| Coupling (DFn = 1, DFd = 26) | F = 0.08 | F = 1.23 | F = 1.23 |
| p = 0.7832 | p = 0.2760 | p = 0.4929 | |
| PM vs. FXTAS | |||
| ROS (DFn = 1, DFd = 35) | F = 0.36 | F = 9.36 | F = 0.42 |
| p = 0.5537 | p = 0.0042 | p = 0.5230 | |
| CS (DFn = 1, DFd = 41) | F = 2.20 | F = 0.50 | F = 1.67 |
| p = 0.1461 | p = 0.4839 | p = 0.2029 | |
| M/G (DFn = 1, DFd = 40) | F = 2.42 | F = 0.28 | F = 1.89 |
| p = 0.1279 | p = 0.5971 | p = 0.1766 | |
| S (DFn = 1, DFd = 39) | F = 1.24e-004 | F = 3.48 | F = 0.05 |
| p = 0.9912 | p = 0.0697 | p = 0.8193 | |
| αGP (DFn = 1, DFd = 39) | F = 0.09 | F = 0.11 | F = 0.11 |
| p = 0.7604 | p = 0.7376 | p = 0.7408 | |
| CCO (DFn = 1, DFd = 41) | F = 0.55 | F = 2.54 | F = 0.26 |
| p = 0.4632 | p = 0.1189 | p = 0.6161 | |
| Basal (DFn = 1, DFd = 40) | F = 0.40 | F = 0.65 | F = 0.55 |
| p = 0.5296 | p = 0.4242 | p < 0.4632 | |
| Coupling (DFn = 1, DFd = 40) | F = 1.71e-003 | F = 5.00 | F = 0.14 |
| p = 0.9672 | p = 0.0312 | p = 0.7118 | |
αGP, alpha-glycerophosphate; Basal, glucose-sustained mitochondrial ATP production; CCO, cytochrome c oxidase; CS, citrate synthase activity; M/G, malate/glutamate; ROS, reactive oxygen species; S, succinate. DF, degrees of freedom; DFn, number of groups -1; DFd, number of subjects – DFn. Numerosity of the groups is as follows. For the comparison between controls and PM: younger controls, n = 4; older controls n = 4; younger PM, n = 7, older PM, n = 13. For the comparison between younger and older carriers: younger PM, n = 17; older PM, n = 5; younger FXTAS, n = 5; older FXTAS, n = 15). Note: in some instances, outcomes for 1–6 samples were not tested for lack of biological material. Bolded are statistically significant p values (<0.05).